www.fdanews.com/articles/204164-cellmax-lifes-cancer-blood-test-designated-fda-breakthrough-device
![CellMax Life Logo](https://www.fdanews.com/ext/resources/test/Device_Images6/CellMaxlife-Logo.png?t=1630356022&width=430)
CellMax Life’s Cancer Blood Test Designated FDA Breakthrough Device
August 30, 2021
Molecular diagnostics company CellMax Life’s FirstSight pre-cancer and cancer detection blood test has received the FDA’s Breakthrough Device designation.
The test is designed to detect and measure colorectal neoplasia-associated epithelial cells and DNA markers in human blood. The results, combined with age and gender, are integrated into a proprietary algorithm to generate a result of either low or high-risk for advanced neoplasia.
The test runs on the Sunnyvale, Calif.-based company’s proprietary platform for detecting cancer and pre-cancer.